CD55 Antibody (143-30): sc-21769

CD55 Antibody (143-30) is a mouse monoclonal IgG1 antibody that detects CD55 in mouse, rat, and human samples through applications such as western blotting (non-reducing), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD55, also known as decay accelerating factor (DAF), is a glycosylphosphatidylinositol (GPI)-anchored single-chain glycoprotein that plays a crucial role in the regulation of the complement system, which is essential for immune defense. By inhibiting the formation of the C3 convertase enzyme complex, CD55 prevents the amplification of the complement cascade, thereby protecting cells from complement-mediated lysis and the formation of the membrane attack complex. This protective function is particularly important in tissues that are exposed to serum, as CD55 is expressed on a variety of cells, including both hematopoietic and non-hematopoietic cells. The ability of CD55 to modulate complement activity is vital for maintaining cellular integrity and preventing unwanted tissue damage during immune responses, making CD55 a significant target for research in immunology and therapeutic interventions. Anti-CD55 antibody (143-30) is an invaluable tool for studying the dynamics of complement regulation and its implications in various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD55 Antibody (143-30) References:

1. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis.  |  Ozen, A., et al. 2017. N Engl J Med. 377: 52-61. PMID: 28657829
2. CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma.  |  Yoda, H. and Weiss, WA. 2022. Neuro Oncol. 24: 886-887. PMID: 35090034
3. CD55 in cancer: Complementing functions in a non-canonical manner.  |  Bharti, R., et al. 2022. Cancer Lett. 551: 215935. PMID: 36216147
4. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.  |  Shao, F., et al. 2022. Nat Cancer. 3: 1192-1210. PMID: 36271172
5. CD39+CD55- Fb Subset Exhibits Myofibroblast-Like Phenotype and Is Associated with Pain in Osteoarthritis of the Knee.  |  Tsuchiya, M., et al. 2023. Biomedicines. 11: PMID: 38002046
6. CD55 Deficiency With Budd-Chiari Syndrome Treated by Liver Transplantation and Eculizumab.  |  Ohlsson, S., et al. 2023. Pediatrics. 152: PMID: 38018238
7. Role of PDGFRA+ cells and a CD55+ PDGFRALo fraction in the gastric mesenchymal niche.  |  Manieri, E., et al. 2023. Nat Commun. 14: 7978. PMID: 38042929
8. Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.  |  Ozen, A., et al. 2024. Lancet. 403: 645-656. PMID: 38278170
9. KLF4 and CD55 expression and function depend on each other.  |  An, FQ., et al. 2023. Front Immunol. 14: 1290684. PMID: 38406578
10. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.  |  Bharti, R., et al. 2024. Mol Cancer. 23: 121. PMID: 38853277

The preferred CD55 antibody is CD55 Antibody (NaM16-4D3): sc-51733.